In the midst of the ongoing Coronavirus (COVID-19) global pandemic, Cure SMA is excited to announce its new funding for the Pediatric Neuromuscular Clinical Research Network (PNCRN). In 2020, Cure SMA will provide ...
Cure SMA is proud to share with the SMA community that it has published a paper in the Orphanet Journal of Rare Diseases, titled ‘The SMA Clinical Trial Readiness Program: Creation ...
Cure SMA is excited to reunite the SMA community for the 2021 Annual SMA Conference in Austin, Texas from Thursday, June 10 – Sunday, June 13, 2021. If the unexpected circumstances of 2020 ...
Cure SMA has released the agenda and registration details for the 2020 Virtual SMA Conference, which will be held from Monday, June 8th – Friday, June 12th. We greatly look forward to virtually ...
Cure SMA will host our first-ever Virtual Walk-n-Roll Celebration Ceremony on Saturday, May 30, 2020 at 11 a.m. EDT/10 a.m. CDT/9 a.m. MDT/8 a.m. PDT. Join us as we celebrate everything our community has achieved ...
New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of SMA Patients Biogen Inc. recently announced additional data from the SPINRAZA (nusinersen) clinical development program that further demonstrate the ...
Cure SMA has been hosting the Annual SMA Conference since 1988, bringing together leading researchers, clinicians, affected individuals, and families living with SMA. The weekend has traditionally been filled with a wide variety ...
For the past two years, Cure SMA’s Summit of Strength program has brought together thousands of SMA community members for the opportunity to network and learn about the latest advances in treatment, care, ...
Cure SMA has always been about creating community. During these exceptional times, we know individuals and families with SMA need us now more than ever. That is why Cure SMA is excited to ...
Dear Members of the SMA Community, In light of the COVID-19 pandemic and the burden it has placed on our healthcare system, Biogen is working with health systems, institutions, physicians, patients and their ...
Scholar Rock recently reported financial results for the first quarter ending March 31, 2020, highlighting progress and upcoming milestones for its pipeline programs—include the SRK-015 program for spinal muscular atrophy ...
Genentech, a member of the Roche Group, today presented 1-year data from FIREFISH Part 2, a pivotal global study evaluating risdiplam in infants aged 1-7 months old with symptomatic Type 1 spinal ...
